文献速递泌尿生殖技术与安全PETCT

预测生化复发前列腺癌患者18F-DCFPyL-PET/CT扫描阳性

Predicting 18F-DCFPyL-PET/CT Scan Positivity in Prostate Cancer Patients with Biochemical Recurrence.
PubMed 文献 · Acad Radiol · 2023-09-27

本研究回顾性分析199例根治性前列腺切除或放疗后生化复发且常规影像阴性的前列腺癌患者,评估18F-DCFPyL-PET/CT阳性及骨盆外病变的预测因素。多因素分析显示PSA和PSAdt是扫描阳性及骨盆外病变的持续显著预测因素,列线图可能有助于筛选适合该检查的患者。

要点

  • PSA和PSAdt是生化复发前列腺癌患者18F-DCFPyL-PET/CT阳性及骨盆外病变的持续显著预测因素。
  • 根治性前列腺切除队列中,扫描阳性预测模型AUC为80%,骨盆外病变预测模型AUC为78%。
  • 放疗队列中骨盆外病变预测模型AUC为82%,但扫描阳性因仅7例阴性而无法建模。

核心结论

  • PSA和PSAdt是生化复发前列腺癌患者18F-DCFPyL PET/CT阳性及骨盆外病变的持续显著预测因素,按原发局部治疗分组可纳入更多预测变量如生化复发时间。

研究设计与样本

  • 回顾性分析一项前瞻性单中心机构审查委员会批准的研究,纳入199例生化复发且常规影像阴性的前列腺癌患者,其中根治性前列腺切除127例、放疗72例,均行18F-DCFPyL-PET/CT,采用单因素和多因素逻辑回归分析预测因素。

诊断标准与关键数值

  • 根治性前列腺切除队列多因素回归显示原发ISUP分级、PSA、PSAdt和生化复发至扫描时间(月)为扫描阳性及骨盆外病变的预测因素,AUC分别为80%和78%。
  • 放疗队列多因素回归显示PSA、PSAdt和生化复发时间(月)为骨盆外病变的预测因素,AUC为82%。
  • 根治性前列腺切除后切缘阳性与阴性均与扫描阳性或骨盆外阳性病灶无关。

临床应用与阅片要点

  • 作者认为该列线图可能有助于筛选最适合行18F-DCFPyL-PET/CT检查的患者;根治性前列腺切除后切缘状态与扫描阳性及骨盆外病灶无关。

局限性

  • 放疗队列仅7例患者扫描阴性,无法分析扫描阳性的预测模型,仅评估了骨盆外病变的存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To analyze variables that can predict the positivity of 18F-DCFPyL- positron emission tomography/computed tomography (PET/CT) and extent of disease in patients with biochemically recurrent (BCR) prostate cancer after primary local therapy with either radical prostatectomy or radiation therapy.

MATERIALS AND METHODS: This is a retrospective analysis of a prospective single institutional review board-approved study. We included 199 patients with biochemical recurrence and negative conventional imaging after primary local therapies (radical prostatectomy n = 127, radiation therapy n = 72). All patients underwent 18F-DCFPyL-PET/CT. Univariate and multivariate logistic regression analyses were used to determine predictors of a positive scan for both cohort of patients. Regression-based coefficients were used to develop nomograms predicting scan positivity and extra-pelvic disease. Decision curve analysis (DCA) was implemented to quantify nomogram's clinical benefit.

RESULTS: Of the 127 (63%) post-radical prostatectomy patients, 91 patients had positive scans - 61 of those with intrapelvic lesions and 30 with extra-pelvic lesions (i.e., retroperitoneal or distant nodes and/or bone/organ lesions). Of the 72 post-radiation therapy patients, 65 patients had positive scans - 39 of them had intrapelvic lesions and 26 extra-pelvic lesions. In the radical prostatectomy cohort, multivariate regression analysis revealed original International Society of Urological Pathology category, prostate-specific antigen (PSA), prostate-specific antigen doubling time (PSAdt), and time from BCR (mo) to scan were predictors for scan positivity and presence of extra-pelvic disease, with an area under the curve of 80% and 78%, respectively. Positive versus negative tumor margin after radical prostatectomy was not related to scan positivity or to the presence of positive extra-pelvic foci. In the radiation therapy cohort, multivariate regression analysis revealed that PSA, PSAdt, and time to BCR (mo) were predictors of extra-pelvic disease, with area under the curve of 82%. Because only seven patients in the radiation therapy cohort had negative scans, a prediction model for scan positivity could not be analyzed and only the presence of extra-pelvic disease was evaluated.

CONCLUSION: PSA and PSAdt are consistently significant predictors of 18F-DCFPyL PET/CT positivity and extra-pelvic disease in BCR prostate cancer patients. Stratifying the patient population into primary local treatment group enables the use of other variables as predictors, such as time since BCR. This nomogram may guide selection of the most suitable candidates for 18F-DCFPyL-PET/CT imaging.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Lee KH, Mena E, Shih J, et al. Predicting 18F-DCFPyL-PET/CT Scan Positivity in Prostate Cancer Patients with Biochemical Recurrence. Acad Radiol. 2023. PMID: 37775447. doi:10.1016/j.acra.2023.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。